TP53 and ovarian cancer: Expression of wild-type p53 was associated with low MGMT level in primary ovarian cancer, supporting the view that downregulation of basal MGMT promoter activity by p53 wild type is also relevant in tumour cells in vivo (Hengstler et al, 1999).